The potent and selective α4β2*/α6*‐nicotinic acetylcholine receptor partial agonist 2‐[5‐[5‐((S)Azetidin‐2‐ylmethoxy)‐3‐pyridinyl]‐3‐isoxazolyl]ethanol demonstrates antidepressive‐like behavior in animal models and a favorable ADME‐tox profile. Issue 2 (12th March 2014)

• Record Type: Journal Article
• Authors: Yu, Li‐Fang; Brek Eaton, J.; Zhang, Han‐Kun; Sabath, Emily; Hanania, Taleen; Li, Guan‐Nan; van, Richard B.; Whiteaker, Paul; Liu, Qiang; Wu, Jie; Chang, Yong‐Chang; Lukas, Ronald J.; Brunner, Dani; Kozikowski, Alan P.
• Is Part Of: Pharmacology research & perspectives. Volume 2:Issue 2(2014:Apr.)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2014-03-12
• Subjects: Pharmacology -- Periodicals; Drug development -- Periodicals; 615.105
• DOI: 10.1002/prp2.26
• Languages: English
• ISSNs: 2052-1707

Abstract

<abstract abstract-type="main" id="prp226-abs-0001"> <title>Abstract</title> <p>Preclinical and clinical studies demonstrated that the inhibition of cholinergic supersensitivity through nicotinic antagonists and partial agonists can be used successfully to treat depressed patients, especially those who are poor responders to selective serotonin reuptake inhibitors (SSRIs). In our effort to develop novel antidepressant drugs, LF‐3‐88 was identified as a potent nicotinic acetylcholine receptor (nAChR) partial agonist with subnanomolar to nanomolar affinities for <italic>β</italic>2‐containing nAChRs (<italic>α</italic>2<italic>β</italic>2, <italic>α</italic>3<italic>β</italic>2, <italic>α</italic>4<italic>β</italic>2, and <italic>α</italic>4<italic>β</italic>2*) and superior selectivity away from <italic>α</italic>3<italic>β</italic>4 − (<italic>K</italic><sub>i</sub> > 10<sup>4</sup> nmol/L) and <italic>α</italic>7‐nAChRs (<italic>K</italic><sub>i</sub> > 10<sup>4</sup> nmol/L) as well as 51 other central nervous system (CNS)‐related neurotransmitter receptors and transporters. Functional activities at different nAChR subtypes were characterized utilizing <sup>86</sup>Rb<sup>+</sup> ion efflux assays, two‐electrode voltage‐clamp (TEVC) recording in oocytes, and whole‐cell current recording measurements. In mouse models, administration of LF‐3‐88 resulted in antidepressive‐like behavioral signatures 15 min post injection in the SmartCube<sup>®</sup> test (5 and 10 mg/kg, i.p.; about 45‐min session), decreased immobility in the forced swim test (1–3 mg/kg, i.p.; 1–10 mg/kg, p.o.; 30 min pretreatment, 6‐min trial), and decreased latency to approach food in the novelty‐suppressed feeding test after 29 days chronic administration once daily (5 mg/kg but not 10 mg/kg, p.o.; 15‐min trial). In addition, LF‐3‐88 exhibited a favorable profile in pharmacokinetic/ADME‐Tox (absorption, distribution, metabolism, excretion, and toxicity) assays. This compound was also shown to cause no mortality in wild‐type Balb/CJ mice when tested at 300 mg/kg. These results further support the potential of potent and selective nicotinic partial agonists for use in the treatment of depression.</p> </abstract>